Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02358694 · ClinicalTrials.gov registry record · NA
Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS
A NA study, sponsored by Connecticut Children's Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT02358694 is a NA study that has completed, run by Connecticut Children's Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT02358694, a NA study, has completed, sponsored by Connecticut Children's Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study is being conducted to see if serum-derived bovine immunoglobulin/protein isolate (SBI) is safe and well tolerated in pediatric patients with IBS-D. Main Hypothesis :Pediatric patients with IBS-D, who take SBI, will have no significant adverse events at 4 and 8 weeks and their quality of life will be better than the patients who receive placebo.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Serum-Derived Bovine Immunoglobulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-06-15 |
| Est. Completion | 2015-06-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02358694
The ClinicalTrials.gov registry entry for NCT02358694 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Connecticut Children's Medical Center, which has 55 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02358694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02358694 about?
NCT02358694 is a clinical study titled "Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS". This study is being conducted to see if serum-derived bovine immunoglobulin/protein isolate (SBI) is safe and well tolerated in pediatric patients with IBS-D. Main Hypothesis :Pediatric patients with IBS-D, who take SBI, will have no significant adverse events at 4 and 8 weeks and their quality of ...
What is the current status of trial NCT02358694?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2014-06-15. Estimated completion is 2015-06-01.
What interventions are being tested in trial NCT02358694?
The interventions under investigation include: Placebo (OTHER), Serum-Derived Bovine Immunoglobulin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02358694?
This trial is sponsored by Connecticut Children's Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.